The FDA approved the first generic version of the Johnson & Johnson drug Doxil on Monday, which is used to treat multiple myeloma, ovarian cancer and AIDS-related Kaposi's sarcoma. The generic version, which is made by Sun Pharma Global FZE, could help solve a Doxil shortage brought about by quality control problems in the manufacturing process.
Sexual and reproductive health risks following treatment from childhood, adolescent and young adult cancer vary depending on cancer type, age at diagnosis and therapy, according to a review in the Journal of Clinical Oncology. Possible long-term sexual and reproductive complications should be discussed by oncologists and cancer patients before treatment begins, researchers said.
Energy intake and density are linked to energy balance in advanced cancer patients but are adversely affected by systemic inflammation, according to Swedish research published in the journal Clinical Nutrition. Researchers said it's important to target inflammation when using nutrition support to prevent or treat cancer cachexia, and they suggested using energy-dense foods and beverages because weight loss shows a negative energy balance that leads to poorer outcomes.
A KLAS Research report finds health care groups are dissatisfied with major vendors' oncology IT systems, citing reporting and alerts as the two most troubling aspects of the technology. Health groups also cited meaningful use as a major challenge involving the technology, saying vendors differ in their capabilities to provide MU support.